文章核心观点 - 律所Levi & Korsinsky通知Cerevel Therapeutics Holdings投资者有关该公司的证券集体诉讼 [1] 诉讼相关信息 诉讼类别定义 - 诉讼旨在代表受证券欺诈不利影响的Cerevel Therapeutics Holdings投资者挽回损失 [2] - 涵盖2023年10月11日至2024年8月1日期间出售或处置Cerevel公开交易普通股的人或实体 [2] - 包括截至2024年1月8日记录日期持有Cerevel股份并有权对Cerevel与AbbVie合并进行投票的人或实体 [2] - 涉及2023年10月16日左右与Bain Capital购买股份同时出售Cerevel股票的人或实体 [2] 案件详情 - Cerevel 2023年10月16日二次股票发行文件及其他公开声明遗漏AbbVie以远超每股22.81美元发行价收购Cerevel的重大事实，人为压低股价直至合并宣布 [3] - 控股股东Bain Capital在掌握AbbVie收购意向的重大非公开信息情况下，以人为压低价格从10月发行中收购Cerevel股份 [3] - 2023年12月6日Cerevel宣布AbbVie以每股45美元收购，Bain因此获利超1.2亿美元 [3] - Cerevel 2024年1月18日代理声明在AbbVie对Cerevel兴趣的真实性质和时间上误导投资者 [3] 后续安排 - 若在相关时间段内遭受损失，投资者需在2025年6月3日前申请被法院指定为首席原告，不担任首席原告也可参与赔偿分配 [4] 律所优势 - Levi & Korsinsky过去20年为受害股东争取数亿美元赔偿，在复杂证券诉讼方面经验丰富 [5] - 公司有超70名员工服务客户，连续七年跻身美国证券诉讼顶级律所前50 [5] 联系方式 - 律所Levi & Korsinsky，联系人Joseph E. Levi和Ed Korsinsky [6] - 地址为纽约市白厅街33号17楼，邮编10004 [6] - 邮箱jlevi@levikorsinsky.com，电话(212) 363 - 7500，传真(212) 363 - 7171，网址www.zlk.com [6]

股票表现 - AbbVie Inc ABBV 股价周二走高 过去一周涨幅超过12% [1] - 目前处于超买状态 可能吸引卖家入场并压低股价 [1] - Benzinga技术分析师团队将其选为"当日股票" [1] 技术分析 - 超买指股票动量超出正常交易区间 通常伴随价格回调 [1] - 相对强弱指数(RSI)是常用动量指标 默认采用14天周期 [4] - 14天RSI显示中性 因当前价格与两周前基本持平 [4] - 调整为5天RSI后显示严重超买状态 [4] 交易策略 - 均值回归策略认为超买状态预示价格下跌 部分交易者可能提前抛售 [2] - 指标预设参数可能失效 根据市况调整周期参数更有效 [5] - 当前5天RSI比14天RSI更能反映AbbVie近期涨势 [5]

产品批准与适应症 - RINVOQ成为美国首个也是唯一一个获批用于治疗成人巨细胞动脉炎(GCA)的口服JAK抑制剂[1] - 这是RINVOQ在美国获批的第九个适应症，覆盖风湿病学、胃肠病学和皮肤病学领域[1] - 欧洲委员会近期也批准了RINVOQ用于治疗成人GCA患者[1] 临床试验数据 - 关键性3期SELECT-GCA试验结果显示，46.4%接受RINVOQ 15 mg联合26周类固醇减量方案的患者在第12至52周达到持续缓解，显著优于安慰剂组的29.0%[2] - 试验包含428名GCA患者，采用多中心、随机、双盲、安慰剂对照设计[6] - 安全性特征与其他已获批适应症基本一致[2] 疾病背景与市场机会 - GCA是西方国家成人最常见的血管炎，主要影响50岁以上高加索女性(70-80岁高发)[2][7] - 未经治疗的GCA可能导致失明、主动脉瘤或中风等严重后果[2] - 目前糖皮质激素仍是主要治疗手段，但存在显著药物毒性且复发率高[2] 产品管线与研发进展 - RINVOQ正在针对斑秃、化脓性汗腺炎、大动脉炎等5种适应症进行3期临床试验[10] - 该药物是AbbVie科学家自主发现并开发的JAK抑制剂，通过选择性抑制JAK1/JAK3发挥作用[9] - 在人类白细胞细胞试验中显示出对JAK1/JAK3介导的STAT磷酸化更强抑制作用[9] 商业化支持 - 公司提供患者支持计划，符合条件的商业保险患者每月自付费用可降至0美元[8] - 未投保或无力支付的患者可通过myAbbVieAssist项目获得援助[8] - 全球处方信息存在差异，需参考各国产品标签[29] 公司战略与行业定位 - AbbVie在风湿病领域深耕20余年，致力于改善风湿病患者治疗结局[30] - 公司聚焦免疫学、肿瘤学、神经科学和眼科等关键治疗领域创新药物开发[32] - 通过持续探索新靶点和通路，提升对免疫介导炎症疾病的治疗水平[31]

NEW YORK, April 29, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerevel Therapeutics Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all persons or entities that: (a) sold or otherwise disposed of the publicly-traded c ...

The positive, post-earnings momentum lifting AbbVie's (ABBV 3.57%) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session. The key reason was a pair of bullish analyst notes on its business. That rise meant the stock easily beat the S&P 500 index, which could only manage a less than 0.1% gain. Still flying after first-quarter resultsOf the two notes, arguably the more impactful was the one BMO Capital's Evan David Seigerman published ...

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/cerevel-therapeutics-holdings-inc-loss-submission-form/?id=1450 ...

CONTACT US HERE: NEW YORK, April 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ABBV during the timef ...

President Trump told attendees at the National Republican Congressional Committee dinner on April 8, "We're going to be announcing very shortly a major tariff on pharmaceuticals." The president believes these tariffs will push drugmakers to manufacture their products in the U.S. instead of in other countries. Importantly, AbbVie's increased full-year earnings guidance included a disclaimer. The company noted that the guidance "is based on the existing trade environment and does not reflect any trade policy ...

On April 25, AbbVie (NYSE: ABBV ) (NEOE: ABBV:CA ) released financial results for the first three months of 2025, which not only once again beat the expectations of Wall Street analysts but, more importantly, under the leadership of Rob Michael, itsWith over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, co ...

核心观点 - 在经济环境充满挑战的背景下，股息股票因其韧性和稳定回报成为投资组合的优选 [1] - 推荐四支优质股息股票：艾伯维、安进、百时美施贵宝和硕腾 [2] 艾伯维 (AbbVie) - 核心业务聚焦免疫学领域，主力产品Skyrizi和Rinvoq推动收入增长 [3] - 管理层将Skyrizi和Rinvoq的2027年收入预期上调40亿美元至超过310亿美元 [4] - 其他产品如偏头痛治疗药Qulipta和肉毒杆菌品牌Botox贡献稳定收入 [5] - 股息连续53年增长，远期股息率达3.9%，显著高于标普500平均1.3% [5] 安进 (Amgen) - 尽管减肥药MariTide二期临床试验未达预期，仍具备商业化潜力 [6] - 拥有超过10款重磅药物，哮喘药Tezspire和甲状腺眼病药Tepezza为增长引擎 [7] - 股息自2011年以来增长750%，远期收益率超3.5% [7][8] 百时美施贵宝 (Bristol Myers Squibb) - 面临Opdivo和Eliquis等核心药物专利到期挑战，但通过新药获批缓解压力 [9] - 贫血药Reblozyl和抗癌药Opdualag等新产品将驱动长期增长 [10] - 过去十年股息增长68%，当前股息率高达5.1% [11] 硕腾 (Zoetis) - 全球动保行业龙头，拥有15款年销售额超1亿美元的产品和300条产品线 [12] - 主力产品Apoquel面临竞争，但新药Solensia和Librela（治疗宠物骨关节炎疼痛）将推动增长 [13] - 过去十年股息增长500%，当前股息率1.4%但无削减风险 [14]